Biogen Inc (BIIB)

Receivables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	9,835,600	9,993,300	9,971,500	10,104,600	10,173,400	10,363,200	10,633,600	10,819,500	10,981,700	11,100,500	11,697,700	12,604,300	13,444,600	14,263,300	14,487,300	14,422,400	14,377,900	14,232,900	14,071,800	13,811,600
Receivables	US$ in thousands	1,664,100	—	—	1,634,400	1,705,000	1,568,800	1,567,600	1,632,000	1,549,400	1,723,000	1,688,000	1,854,300	1,913,800	2,024,900	2,133,600	2,092,600	1,880,500	1,933,500	1,959,600	2,088,900
Receivables turnover		5.91	—	—	6.18	5.97	6.61	6.78	6.63	7.09	6.44	6.93	6.80	7.03	7.04	6.79	6.89	7.65	7.36	7.18	6.61

December 31, 2023 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $9,835,600K ÷ $1,664,100K
= 5.91

The receivables turnover ratio for Biogen Inc has been relatively consistent over the past eight quarters, ranging from 4.52 to 5.35. The ratio measures how efficiently the company is able to collect payments from its customers. A higher turnover ratio indicates that the company is able to collect payments more quickly, which is generally seen as a positive sign of strong accounts receivables management.

In Biogen Inc's case, the receivables turnover ratio has shown a slight decrease in recent quarters, from 5.35 in Q1 2022 to 4.68 in Q4 2023. This may suggest that the company is taking slightly longer to collect payments from its customers, which could potentially impact its cash flow and liquidity. However, it is important to note that a single ratio may not provide a full picture, and it is recommended to analyze other financial ratios and factors to get a more comprehensive understanding of the company's financial performance.